Alpha 2.0

» Articles » PMID: 17589894

Effect of Targeted Magnetic Nanoparticles Containing 5-FU on Expression of Bcl-2, Bax and Caspase 3 in Nude Mice with Transplanted Human Liver Cancer

Overview

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2007 Jun 26

PMID 17589894

Citations 7

Authors

Authors

Jian-Ming Wang

Bao-Lai Xiao

Jian-Wei Zheng

Hai-Bing Chen

Sheng-quan Zou

Affiliations

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the anti-tumor effect and mechanisms of magnetic nanoparticles targeting hepatocellular carcinoma.

Methods: Human hepatocellular carcinoma was induced in nude mice, and the mice were randomly divided into group A receiving normal saline, group B receiving magnetic nanoparticles containing 5-fluorouracil (5-FU), group C receiving 5-FU, and group D receiving magnetic nanoparticles containing 5-FU with a magnetic field built in tumor tissues. The tumor volume was measured on the day before treatment and 1, 4, 7, 10 and 13 d after treatment. Tumor tissues were isolated for examination of the expression of bcl-2, bax and caspase 3 by immunohistochemical method, reverse transcription polymerase chain reaction and Western blotting.

Results: The tumor volume was markedly lower in groups C and D than in groups A and B (group C or D vs group A or B, P<0.01). The volume was markedly lower in group D than in group C (P<0.05). The expression of protein and mRNA of bcl-2 was markedly lower in groups C and D than in groups A and B (group C or D vs group A or B, P<0.01), and was markedly lower in group D than in group C (P<0.01). The expression of bax and caspase 3 in groups C and D was significantly increased, compared with that in groups A and B (P<0.01).

Conclusion: The targeted magnetic nanoparticles containing 5-FU can improve the chemotherapeutic effect of 5-FU against hepatocellular carcinoma by decreasing the expression of bcl-2 gene, and increasing the expression of bax and caspase 3 genes.

Citing Articles

Poly (N-Vinylcaprolactam-Grafted-Sodium Alginate) Based Injectable pH/Thermo Responsive In Situ Forming Depot Hydrogels for Prolonged Controlled Anticancer Drug Delivery; In Vitro, In Vivo Characterization and Toxicity Evaluation.

Khan S, Usman Minhas M, Aqeel M, Shah I, Khan S, Kazi M Pharmaceutics. 2022; 14(5).

PMID: 35631636 PMC: 9143242. DOI: 10.3390/pharmaceutics14051050.

Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.

Hu Z, Lv G, Li Y, Li E, Li H, Zhou Q J Exp Clin Cancer Res. 2016; 35:71.

PMID: 27102814 PMC: 4840943. DOI: 10.1186/s13046-016-0349-4.

Combination of ultrasound and newly synthesized magnetic nanocapsules affects the temperature profile of CT26 tumors in BALB/c mice.

Shakeri-Zadeh A, Khoei S, Khoee S, Sharifi A, Shiran M J Med Ultrason (2001). 2015; 42(1):9-16.

PMID: 26578485 DOI: 10.1007/s10396-014-0558-4.

Vanadium toxicity in the thymic development.

Cui W, Guo H, Cui H Oncotarget. 2015; 6(30):28661-77.

PMID: 26416460 PMC: 4745684. DOI: 10.18632/oncotarget.5798.

Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.

Chen J, Shao R, Li L, Xu Z, Gu W Int J Nanomedicine. 2014; 9:3403-11.

PMID: 25075187 PMC: 4107171. DOI: 10.2147/IJN.S61633.

References

1.

KERR J, Winterford C, Harmon B . Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73(8):2013-26. DOI: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. View

2.

Duan X, Ou J, Li Y, Su J, Ou C, Yang C . Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol. 2005; 11(30):4740-4. PMC: 4615422. DOI: 10.3748/wjg.v11.i30.4740. View

3.

Gong L, Zhang Y, Liu S . Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int. 2004; 3(3):365-8. View

4.

Keane M, Ettenberg S, Nau M, RUSSELL E, Lipkowitz S . Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999; 59(3):734-41. View

5.

Kogure T, Ueno Y, Iwasaki T, Shimosegawa T . The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2003; 53(4):296-304. DOI: 10.1007/s00280-003-0725-6. View

6.

Parkin D, Pisani P, Ferlay J . Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80(6):827-41. DOI: 10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p. View

7.

Dizon D, Kemeny N . Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol. 2002; 29(2):126-35. DOI: 10.1053/sonc.2002.31680. View

8.

Thompson C . Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 267(5203):1456-62. DOI: 10.1126/science.7878464. View

9.

Babincova M, Altanerova V, Lampert M, Altaner C, Machova E, Sramka M . Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field. Z Naturforsch C J Biosci. 2000; 55(3-4):278-81. DOI: 10.1515/znc-2000-3-422. View

10.

Widder K, Morris R, Poore G, Howard D, Senyei A . Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol. 1983; 19(1):135-9. DOI: 10.1016/0277-5379(83)90408-x. View

11.

Boyce M, Degterev A, Yuan J . Caspases: an ancient cellular sword of Damocles. Cell Death Differ. 2003; 11(1):29-37. DOI: 10.1038/sj.cdd.4401339. View

12.

Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T . Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res. 2003; 23(2C):1891-7. View

13.

Cohen-Saidon C, Razin E . The involvement of Bcl-2 in mast cell apoptosis. Novartis Found Symp. 2006; 271:191-5. View

14.

Clark J, GLICKSMAN A, Wanebo H . Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer. 1996; 78(3 Suppl):688-93. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<688::AID-CNCR50>3.0.CO;2-R. View

15.

Lubbe A, Bergemann C, Huhnt W, Fricke T, Riess H, Brock J . Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996; 56(20):4694-701. View

16.

Tang Z, Sun F, Tian J, Ye S, Liu Y, Liu K . Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential. World J Gastroenterol. 2002; 7(5):597-601. PMC: 4695559. DOI: 10.3748/wjg.v7.i5.597. View

17.

Shuto T, Kinoshita H, Hirohashi K, Kubo S, Tanaka H, Tsukamoto T . Indications for, and effectiveness of, a second hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology. 1996; 43(10):932-7. View

18.

Blum H . Molecular targets for prevention of hepatocellular carcinoma. Dig Dis. 2002; 20(1):81-90. DOI: 10.1159/000063163. View

19.

Lubbe A, Alexiou C, Bergemann C . Clinical applications of magnetic drug targeting. J Surg Res. 2001; 95(2):200-6. DOI: 10.1006/jsre.2000.6030. View

20.

Sartorius U, Krammer P . Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 2002; 97(5):584-92. DOI: 10.1002/ijc.10096. View